173 related articles for article (PubMed ID: 36416959)
21. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
Tanner M; Hollmén M; Junttila TT; Kapanen AI; Tommola S; Soini Y; Helin H; Salo J; Joensuu H; Sihvo E; Elenius K; Isola J
Ann Oncol; 2005 Feb; 16(2):273-8. PubMed ID: 15668283
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
23. Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma.
Anandappa G; Chau I
Hematol Oncol Clin North Am; 2017 Jun; 31(3):529-544. PubMed ID: 28501092
[TBL] [Abstract][Full Text] [Related]
24. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.
Kato H; Arao T; Matsumoto K; Fujita Y; Kimura H; Hayashi H; Nishiki K; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Yasuda T; Okuno K; Shiozaki H; Nishio K
Int J Oncol; 2013 Apr; 42(4):1151-8. PubMed ID: 23426935
[TBL] [Abstract][Full Text] [Related]
25.
Carter JH; Cottrell CE; McNulty SN; Vigh-Conrad KA; Lamp S; Heusel JW; Duncavage EJ
Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 28835367
[No Abstract] [Full Text] [Related]
26. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
[TBL] [Abstract][Full Text] [Related]
27. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
28. FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma.
Wang Y; Shi T; Wang X; Hu J; Yu L; Liu Q; Wu N; Liu B; Wei J
J Transl Med; 2021 Sep; 19(1):401. PubMed ID: 34551773
[TBL] [Abstract][Full Text] [Related]
29. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization.
Ooi A; Kobayashi M; Mai M; Nakanishi I
Lab Invest; 1998 Mar; 78(3):345-51. PubMed ID: 9520947
[TBL] [Abstract][Full Text] [Related]
30. Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
Shoji H; Yamada Y; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Anticancer Res; 2015 Sep; 35(9):5055-61. PubMed ID: 26254407
[TBL] [Abstract][Full Text] [Related]
31. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract][Full Text] [Related]
32. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
[TBL] [Abstract][Full Text] [Related]
33. Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Nakamura H; Dobashi Y
Mod Pathol; 2015 Jun; 28(6):861-71. PubMed ID: 25743022
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma.
Schäfer MH; Lingohr P; Sträßer A; Lehnen NC; Braun M; Perner S; Höller T; Kristiansen G; Kalff JC; Gütgemann I
Hum Pathol; 2015 Oct; 46(10):1488-95. PubMed ID: 26239623
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma.
Jung EJ; Jung EJ; Min SY; Kim MA; Kim WH
Hum Pathol; 2012 Oct; 43(10):1559-66. PubMed ID: 22440694
[TBL] [Abstract][Full Text] [Related]
36. [Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization].
Raskin GA; Mukhina MS; Kravtsova ED; Tsimafeyeu IV; Tyulandin SA; Belyak NP; Kleshchev MA; Orlova RV
Arkh Patol; 2023; 85(3):40-45. PubMed ID: 37272439
[TBL] [Abstract][Full Text] [Related]
37. FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort.
Schrumpf T; Behrens HM; Haag J; Krüger S; Röcken C
PLoS One; 2022; 17(2):e0264011. PubMed ID: 35167603
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implications of
Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
[TBL] [Abstract][Full Text] [Related]
39. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
[TBL] [Abstract][Full Text] [Related]
40. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
Reichelt U; Duesedau P; Tsourlakis MCh; Quaas A; Link BC; Schurr PG; Kaifi JT; Gros SJ; Yekebas EF; Marx A; Simon R; Izbicki JR; Sauter G
Mod Pathol; 2007 Jan; 20(1):120-9. PubMed ID: 17143264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
